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Edited by Lukas HuberAbstract p116Rip, originally identiﬁed as a binding partner of
activated RhoA, is an actin-binding protein that interacts with
the regulatory myosin-binding subunit (MBS) of myosin-II
phosphatase and is essential for Rho-regulated cytoskeletal
contractility. Here, we have examined the role of p116Rip in
RhoA-mediated activation of the transcription factor SRF.
We show that p116Rip oligomerizes via its C-terminal coiled-
coil domain and, when overexpressed, inhibits RhoA-induced
SRF activation without aﬀecting RhoA-GTP levels. Mutant
forms of p116Rip that fail to oligomerize or bind to MBS are
still capable of inhibiting SRF activity. Our results suggest that
p116Rip interferes with RhoA-mediated transcription through its
ability to disassemble the actomyosin cytoskeleton downstream
of RhoA.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Coiled-coil1. Introduction
Rho GTPases are involved in a wide range of cellular
responses, ranging from regulation of the actin cytoskeleton
and cell morphology to transcriptional activation and cell cycle
progression [1–3]. Thus, activation of RhoA leads not only to
actomyosin-driven contraction [4,5], but also to activation of
the transcription factor SRF [6]. Changes in actin dynamics
are both necessary and suﬃcient for serum response factor
(SRF) activation [7]. SRF activation is mediated by two distinct
downstream eﬀectors of RhoA, Rho-kinase (ROCK) and
mDia, which act cooperatively to induce F-actin assembly
and stabilization [8,9]; the resulting depletion of G-actin trig-
gers SRF activation [10]. Activated ROCK phosphorylates
the regulatory myosin-binding subunit (MBS) of myosin
light-chain (MLC) phosphatase, thereby stimulating MLC
phosphorylation and actomyosin contractility [11,12].
Using a yeast two-hybrid screen, we have previously identi-
ﬁed a ubiquitously expressed protein of 116 kDa, namedAbbreviations: GFP, green ﬂuorescent protein; GST, glutathione
S-transferase; HA, hemagglutinin; LPA, lysophosphatidic acid; MLC,
myosin light chain;MBS,myosin-binding subunit ofMLCphosphatase;
ROCK, Rho-kinase; SRE, serum response element; SRF, serum resp-
onse factor
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doi:10.1016/j.febslet.2005.09.083p116Rip, that interacted with activated V14RhoA [13]. Subse-
quent studies revealed that p116Rip is an F-actin binding protein
with actin-bundling properties in vitro [14]. Overexpression of
p116Rip disrupts the actin cytoskeleton and thereby inhibits
contractility [13,14], whereas knockdown of p116Rip maintains
cells in a rounded state [15]. We and others found that the C-ter-
minal coiled-coil domain of p116Rip interacts directly with the
regulatoryMBS ofmyosin II phosphatase [15–17]. The availabe
evidence suggests that p116Rip acts as a scaﬀold that links the
MLC phosphatase complex to F-actin [15]. Thus, p116Rip
may interfere with RhoA signaling at multiple levels.
In the present study, we set out to examine the eﬀect of
p116Rip on RhoA-regulated SRF activity, with emphasis on
the role of the coiled-coil domain. We show that: (i) the
coiled-coil domain of p116Rip mediates homo-oligomerization;
and (ii) overexpression of p116Rip inhibits RhoA-mediated SRF
activation without aﬀecting RhoA-GTP levels; (iii) oligomeri-
zation and MBS binding are not required for p116Rip to inhibit
SRF activation. We conclude that p116Rip acts downstream of
ROCK and abrogates RhoA-induced SRF activation through
its ability to disassemble the actin cytoskeleton.2. Materials and methods
2.1. Plasmids
pcDNA3-HA-DNp116Rip, pcDNA3-HA-FLp116Rip, pMT2sm-
FLp116Rip-GST, pcDNA3-HA-NTp116Rip, pcDNA3-HA-CTp116Rip
and pcDNA3-HA-RBDp116Rip have been described elsewhere [13–
15]. SRE.L-luciferase plasmids, GST-C21, pcDNA3-HA-p190RhoGEF
and pMT2sm-HA-p190RhoGEF-DH/PH are described previously [18].
The dominant-active RhoA pMT2sm-myc construct has been described
previously [13]. pcDNA3-HA-PHp116Rip (aa 383–488) was generated
by PCR. pMT2sm-DNp116Rip-GST was constructed by ligation of a
BstXI–SalI, blunt-ended fragment out of FLp116Rip-peGFPN1 into
SmaI cut pMT2sm-GST. pMT2sm-DCp116Rip-GST was generated by
digestion of pMT2sm-FLp116Rip-GST with SmaI and ligation into
SmaI–NotI, blunt-ended pMT2sm-GST. The p116Rip mutants
(L857P/L864P, L905P/I912P, and I919P/L926P) were made with the
QuikChange Site-Directed Mutagenesis Kit (Stratagene) using the
p116Rip mutants (L857P, L905P, and I919P [15]) as a template.
pXJ40-FLAG-p85 (MBS) and pEFBOS-myc-MBS130 were kindly
provided by Dr. T. Leung and Dr. K. Kaibuchi, respectively.2.2. Western blotting, immunoprecipitation, and pull-down assays
COS-7 and HEK293 cells were grown and transfected as described
before [14,15]. COS-7 cells co-expressing various constructs were
scraped in lysis buﬀer A (1% NP-40, 50 mM Tris, pH 7.4, 200 mM
NaCl, 2.5 mM MgCl2, 10% glycerol, supplemented with protease
inhibitors). Immunoprecipitation using hemagglutinin (HA) mAb
(12CA5, ATCC) was performed as described [15]. Western blotting
was performed using myc (9E10, ATCC), HA, or FLAG mAbs (M2,
Sigma).blished by Elsevier B.V. All rights reserved.
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performed as follows. GST fusion proteins were prepared as described
[14]. COS-7 cell lysates were prepared as above, clariﬁed by centrifuga-
tion, and incubated for 3 h at 4 C with GSH-sepharose coupled GST
fusion proteins. Beads were washed, eluted in Laemmli sample buﬀer
and separated by SDS–PAGE and analyzed by Western blotting using
myc or GST mAbs (2F3, ATCC).
2.3. SRF-mediated luciferase gene transcription
HEK293 cells were transfected with pCMV-b-gal (0.2 lg), pSRE.luc
(0.2 lg) and indicated plasmids. The total DNA was 3 lg per well
using pcDNA3 and/or pMT2sm empty vectors. 24 h after transfection
DMEM containing 0.5% FCS was added to the cells. 48 h after trans-
fection, cells were lyzed in 200 ll Reporter Lysis Buﬀer (25 mM Tris–Fig. 1. The coiled-coil domain of p116Rip mediates p116Rip oligomerization.
(TL, left panel) and immunoprecipitates (IP, right panel) were analyzed by
transfected with indicated plasmids. TL (left panel) and GST precipitates
representation of the oligomerization via the coiled-coil domain of p116Rip; +
wt, wild-type p116Rip; NT, N-terminal actin-binding domain [14]; CT, C-term
N-terminal and C-terminal regions, respectively; ND, not determined.HCl, pH 7.8, 2 mM DTT, 2 mM EDTA, 10% glycerol, and 1% Triton
X-100). Luciferase activity was measured at 495 nm using 20 ll of ly-
sate and 50 ll of Luciferase Substrate (Promega). b-Galactosidase
measurements were used to normalise transfection eﬃciency. Lucifer-
ase and b-galactosidase activity were quantiﬁed using a Victor lumino-
meter (Wallac, Turku, Finland). Equal amounts of lysate were
subjected to SDS–PAGE and analyzed by western blotting. Experi-
ments were repeated at least three times.
2.4. RhoA activation assay
RhoA activity in transfected COS-7 cells was analyzed by pull-
down assays using GST-C21 containing the RhoA-binding domain
of Rhotekin as described [18]. 1-oleoyl-LPA was purchased from
Sigma.(A) COS-7 cells were transfected with indicated plasmids. Total lysates
immunoblotting (IB) using a-HA and a-Myc (B) COS-7 cells were
(right panel) were analyzed using a-GST and a-Myc. (C) Schematic
denotes p116Rip oligomerization or MBS binding [15]. –, empty vector;
inal region; RBD, Rho-binding domain [13]; DN and and DC lacks the
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Transfected NIH3T3 cells were analyzed for the presence of stress
ﬁbres as described [14].3. Results and discussion
3.1. The coiled-coil of p116Rip mediates homo-oligomerization
The C-terminal domain of p116Rip (aa 600–1024) contains six
coiled-coil regions, as predicted by the MULTICOIL program
[19] (Fig. S1). This domain was previously found to interact
with the leucine-zipper domains of MBS (MBS85 and
MBS130) [15,17]. We observed that, in COS-7 cell lysates,
Myc-tagged p116Rip co-precipitated with HA-tagged p116Rip,
indicative of oligomerization (Fig. 1A). To investigate whether
oligmerization is mediated by the coiled-coil domain, we ex-
pressed various truncation mutants in COS-7 cells. As shown
in Fig. 1A, N-terminally truncated versions of p116Rip
(HA-tagged) could precipitate Myc-p116Rip, whereas deletion
mutants lacking the coiled-coil region could not. Similarly,
Myc-p116Rip was pulled down by a GST fusion protein of
p116Rip lacking the N-terminal region (DN), but not by a
GST-p116Rip fusion protein lacking the coiled-coil (DC;Fig. 2. (Iso)leucine residues in the coiled-coil of p116Rip mediate homo-oligo
domain of p116Rip. (Iso)leucines in bold were mutated to proline. (B) COS-
plasmid; wt, wild-type p116Rip; TL, total lysates (upper panels); IP, immunop
a higher mobility, consistent with distortion of the coiled-coil structure. (C)
MBS85 and MBS130. COS-7 cells were transfected with plasmids encoding
HA-tagged plasmids. Immunoprecipitation was performed as in B.Fig. 1B). Thus, the p116Rip coiled-coil mediates both homo-
oligomerization and MBS binding (Fig. 1C).
Mutagenesis of (iso)leucine residues (to alanine, valine or
proline) aﬀects coiled-coil stability and abolishes protein–
protein interaction [20,21]. Using various (iso)leucine mutants
(L857P, L905P, I919P, L857P/L864P, L905P/I912P, and
I919P/L926P; Fig. 2A), we found that double mutants L905-
P/I912P and I919P/L926P failed to oligomerize (Fig. 2B), indi-
cating that I(912) and L(926) are critical for oligomerization.
All double mutants failed to interact with MBS (Fig. 2C), indi-
cating that, in addition to L(857) and I(919)[15], residue I(912)
is critical for interaction with MBS. We conclude that an over-
lapping region within the p116Rip coiled-coil domain mediates
both p116Rip–p116Rip and p116Rip-MBS oligomerization.
3.2. p116Rip inhibits RhoA-mediated activation of SRF
Rho GTPases activate the serum response factor (SRF) [6]
through their ability to induce actin polymerization [10]. Since
overexpression of p116Rip interferes with RhoA-induced cyto-
skeletal changes [13,14], we examined how p116Rip may aﬀect
RhoA-mediated SRF activation. We used a reporter assay
in which the luciferase gene is driven by a c-Fos serum-respon-
sive promoter element (pSRE.L) that speciﬁcally reports Rhomerization. (A) Representation of residues 851–1024 of the coiled-coil
7 cells were transfected with indicated plasmids. –, empty HA-tagged
recipitation using a-HA. Note that the double mutant L905P/I912P has
(Iso)leucine residues in the coiled-coil of p116Rip mediate binding to
either FLAG-MBS85 (upper) or Myc-MBS130 (lower) and indicated
6124 J. Mulder et al. / FEBS Letters 579 (2005) 6121–6127signaling [22]. HEK293 cells were co-transfected with pSRE.L,
RhoV14 or the Rho-speciﬁc exchange factor p190RhoGEF
[18] together with p116Rip. As shown in Fig. 3A and B, expres-
sion of p116Rip markedly inhibits SRF activation induced by
either RhoV14 or p190RhoGEF.
3.3. p116Rip does not aﬀect RhoA activation
Given that overexpression of p116Rip inhibits SRF activa-
tion and induces a ‘‘dominant-negative’’ RhoA phenotype
[13,14], we examined the activation state of RhoA in
p116Rip-expressing COS-7 cells using lysophosphatidic acid
(LPA) as an agonist and p190RhoGEF (DH/PH) [18] as a po-
sitive control. Basal Rho-GTP levels were unaﬀected by over-
expression of p116Rip (Fig. 3C), whilst RhoA was activated by
LPA in both control and p116Rip-transfected cells (Fig. 3C).Fig. 3. p116Rip expression interferes with RhoA-mediated SRF activation.
plasmid, b-galactosidase control plasmid, HA-p116Rip and either HA-p190R
was transfected into cells () or cells were transfected with SRE.L-lucifera
Lower panels show the expression of transfected proteins in total cell lysates.
7 cells were transfected with empty vector (), HA-p190RhoGEF-DH/PH, o
1 lMLPA for 3 min. Samples were analyzed for levels of activated RhoA (GT
with a-RhoA, a-myc, and a-HA. Lines indicate duplicate samples. (D) HE
RhoV14 and increasing amounts of HA-p116Ripwt/HA-p116Rip mutants. HAThus, overexpressed p116Rip does not interfere with LPA-in-
duced RhoA activation.
3.4. Inhibition of SRF activity by p116Rip does not depend on its
oligomerization or interaction with MBS
We next examined whether inhibition of SRF activity de-
pends on the ability of p116Rip to homo-oligomerize or/and
to associate with MBS. Wild-type p116Rip, (iso)leucine single
mutants that no longer bind MBS, or (iso)leucine double mu-
tants that fail to interact with both MBS and p116Rip were
co-expressed with activated RhoA in HEK293 cells and SRF
activation was determined. Since the DN and DC truncation
mutants of p116Rip yielded inconclusive results in the luciferase
read-out (data not shown), a p116Rip deletion mutant contain-
ing only the second PH domain was used as a control. As(A,B) HEK293 cells were transfected with SRE.L-luciferase reporter
hoGEF (A), or myc-RhoV14 (B). As negative controls, empty vector
se reporter-, b-galactosidase plasmids, and empty vector (control, C).
(C) p116Rip overexpression does not interfere with RhoA activity. COS-
r p116Rip-myc. Cells were serum-starved overnight and stimulated with
P-RhoA) by immunoblotting using a-RhoA. TL, total lysates analyzed
K293 cells were transiently transfected as in B, with or without myc-
-PHp116Rip was used as a negative control.
Fig. 3 (continued)
Table 1
Summary
SRF activity (%)a MBS interactionb p116Rip interactionb Loss of stress ﬁbresc
RhoV14 100
RhoV14 + p116Rip wt 35 ++ ++ Yes
RhoV14 + p116Rip L857P 40 ± ++ Yes
RhoV14 + p116Rip I919P 46 ± ++ Yes
RhoV14 + p116Rip L905P/I912P 47   Yes
RhoV14 + p116Rip I919P/L926P 35   Yes
RhoV14 + PH-p116Rip 105 ND ND ND
ND, not determined.
aSRF activity induced by RhoA(V14) in HEK293 cells using 1.5 lg of p116Rip plasmid.
bInteraction with p116Rip in COS-7 cells: ++, strong interaction; ±, weak interaction; , no interaction.
cDetermined in NIH3T3 cells upon transfection of p116Rip wt or mutants (see Fig. 4).
Fig. 4. Expression of p116Rip (iso)leucine mutants induces loss of stress ﬁbres. NIH3T3 cells were transfected with HA-tagged p116Rip wild-type (wt),
HA-tagged p116Rip (iso)leucine mutants, GFP or p116Rip-GFP constructs. Stress ﬁbres were analyzed as described [14].
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Fig. 5. Model of p116Rip counteracting the RhoA pathway. RhoA activation leads to reorganization of the actin cytoskeleton through the activation
of its eﬀectors ROCK and mDia, causing accumulation and stabilization of F-actin and increased actomyosin contractility. Consequently, MAL is
no longer sequestered by G-actin and relocates to the nucleus, where it activates SRE-mediated gene expression [10]. p116Rip may interfere with the
RhoA pathway at multiple levels: (i) by direct aﬀecting F-actin leading to inhibition of actomyosin contractility and gene transcription; (ii) by acting
in parallel with MLC phosphatase resulting in reduced actomyosin contractility [15]. SRF, serum response factor; SRE, serum response element;
MAL, megakaryocytic acute leukaemia protein, ROCK, Rho-kinase; LIMK, LIM-kinase; MLC, myosin light chain; MLCP, MLC-phosphatase.
6126 J. Mulder et al. / FEBS Letters 579 (2005) 6121–6127shown in Fig. 3D and summarized in Table 1, wild-type
p116Rip and the (iso)leucine mutants were all capable of inhib-
iting RhoA-induced SRF activation, indicating that the eﬀect
of p116Rip on SRF activation does not depend on oligomeriza-
tion or MBS binding.
3.5. Inhibition of SRF activity by p116Rip correlates with its
capacity to disrupt the cytoskeleton
To examine whether p116Rip modulates Rho-induced SRF
activation through its eﬀect on the F-actin cytoskeleton [14],
we studied the cytoskeletal organization of NIH3T3 cells
expressing the (iso)leucine mutants of p116Rip. Expression of
all mutants resulted in a dramatic loss of stress ﬁbres, similar
to what is observed with wild-type p116Rip (Fig. 4). Less than
15% of the p116Rip wild-type or (iso)leucine mutant-transfec-
ted NIH3T3 cells contain stress ﬁbres, compared to >60% of
green ﬂuorescent protein (GFP)-expressing control cells. Thus,
the eﬀect of p116Rip overexpression on SRF activation closely
correlates with its ability to disrupt the actin cytoskeleton
(Table 1).4. Conclusion
We have shown that p116Rip, through its C-terminal coiled-
coil domain, homo-oligomerizes with itself and hetero-oligo-
merizes with MBS. How oligomerization may aﬀect the
function of p116Rip remains to be examined. The present data
show that p116Rip expression abrogates RhoA signaling to
the nucleus, which is consistent with our previous studies show-
ing that p116Rip expression inversely correlates with an acti-
vated RhoA phenotype [14,15]. Through mutational analysis
we have ruled out the possibility that p116Rip oligomerization
or MBS-p116Rip interaction plays a role in the transcriptionalinhibition by p116Rip. Of note, p116Rip overexpression does
not aﬀect RhoA-GTP levels, which argues against a scenario
in which p116Rip might have intrinsic GAP activity [16].
In conclusion, our studies show that p116Rip overexpres-
sion antagonizes RhoA signaling, not only at the level of
cytoskeletal regulation (as evidenced by loss of stress ﬁbres
and induction of neurite outgrowth [13,14]) but also, as re-
ported here, at the level of gene transcription. However, it
has been unclear at which step in the RhoA signaling path-
way p116Rip acts. Our studies indicate that p116Rip acts
downstream of the RhoA-ROCK pathway, because p116Rip
overexpression does not aﬀect either basal or LPA-induced
levels of RhoA-GTP (Fig. 3C) and, furthermore, knockdown
of p116Rip prevents cell spreading and neurite outgrowth in
response to the ROCK inhibitor Y-27632 [15]. Recent evi-
dence indicates that activation of SRF is regulated by its
ability to sense G-actin levels [7,10]. Since inhibition of
SRF activity by p116Rip correlates with the ability of
p116Rip to disrupt the actin-based cytoskeleton, our data sug-
gest a model in which p116Rip has the potential to disassem-
ble the F-actin cytoskeleton with a concomitant increase in
G-actin levels serving as a trigger for decreased SRF activity.
If and how p116Rip may aﬀect the balance between G- and
F-actin remains to be examined.
Our previous studies suggested that p116Rip acts as a scaﬀold
to target MBS to the actin cytoskeleton [15]. Whilst the RhoA/
ROCK pathway leads to phosphorylation of MLC, the MBS
complex dephoshorylates MLC and thereby antagonizes
RhoA/ROCK signaling [23–25]. As schematicaly illustrated
in Fig. 5, our data support a model in which p116Rip acts
downstream of the Rho/ROCK pathway, acting in concert
with MLC phosphatase and F-actin, to negatively regulate
the RhoA-actin pathway and to attenuate actomyosin contrac-
tility and SRF activity.
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